Parathyroid hyperplasia

Parathyroid hyperplasia is a pathological enlargement of the parathyroid gland tissues, which leads to an excess of parathyroid hormone. This condition may be associated with both primary and secondary causes of parathyroid dysfunction. Hyperplasia may be diffuse or nodose and is one of the most common forms of parathyroid dysfunction, leading to hypercalcemia and associated metabolic disorders. Symptoms may vary from asymptomatic to severe clinical manifestations associated with increased blood calcium levels and the development of osteoporosis, nephrolithiasis, and other complications. This condition requires careful diagnosis and, if necessary, treatment, including both medication and surgical methods.

History of the disease and interesting historical facts

Hyperplasia of the parathyroid glands has been known to the medical community for centuries. The nature of these glands was first described in the 19th century, when anatomists and pathologists began to study their functions and structural features. Scientific works by scientists such as Titius and Kepler, for example, laid the foundation for understanding the role of the parathyroid glands in maintaining calcium and phosphorus homeostasis. An interesting fact is that in 1925, a link between hyperplasia and metabolic disorders in patients with chronic renal failure was first discovered. By the beginning of the 21st century, modern methods for diagnosing and treating hyperplasia had been developed, but many aspects of this disease remain the subject of scientific research, including its relationship with various genetic and environmental factors.

Epidemiology

According to various epidemiological studies, parathyroid hyperplasia usually occurs in 25% patients with primary hyperparathyroidism. Studies show that this disease is more often detected in women than in men, with a ratio of 3:1. At the age of 65 and older, its incidence increases, accounting for 40–60% cases among elderly patients. Experts note that by the age of 50, the incidence rate increases significantly, and this trend continues to be observed with each decade. In certain populations, including people with hereditary syndromes, epidemiological data may show an even higher incidence of hyperplasia. For example, in studies among patients with Menipott syndrome, the incidence of parathyroid hyperplasia reaches 90%.

Genetic predisposition to this disease

Genetic studies suggest that parathyroid hyperplasia may be associated with certain gene mutations, including the MEN1 (Mendelian endocrine neoplasia 1) gene, which is responsible for the development of many endocrine tumors. Mutations in the RET and CDKN1B genes are also associated with multiple endocrine neoplasia syndrome and increase the risk of developing parathyroid hyperplasia. Familial cases of the disease may indicate a hereditary predisposition, as well as the transmission of mutations from generation to generation. However, despite certain genetic markers, most cases of hyperplasia remain sporadic, and their etiology is not fully understood, which emphasizes the need for further research.

Risk factors for the development of this disease

A variety of risk factors may contribute to the development of parathyroid hyperplasia. These include:

• Age: Aging is one of the main risk factors, since the function of the parathyroid glands changes with age.
• Floor: Women are more likely to develop parathyroid hyperplasia than men.
• Heredity: Having a family history of parathyroid disease increases the risk of developing hyperplasia.
• Chronic renal failure: The longer a patient suffers from this disease, the higher the risk of hyperplasia.
• Low Vitamin D: Its deficiency can lead to hyperparathyroidism and subsequent hyperplasia.
• Environmental factors: Exposure to radiation and certain chemicals may trigger changes in the parathyroid glands.

Diagnosis of this disease

Diagnostic methods for hyperplasia of the parathyroid glands are based on the assessment of the clinical picture, laboratory and radiological studies. The main symptoms include:

• Hypercalcemia confirmed by laboratory tests;
• Weakness, fatigue and depressive states;
• Bone pain and joint pain;
• Kidney problems, including stone formation;
• Changes in mental state, such as clouded consciousness.

Laboratory tests include serum calcium and parathyroid hormone levels. Radiologic tests may include ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI) to assess the size of the parathyroid glands.

Primary attention should be given to the differential diagnosis, excluding other conditions associated with hypercalcemia such as primary hyperparathyroidism, malignancies, and flagellation.

Treatment

Treatment for parathyroid hyperplasia depends on the severity of the disease and the associated symptoms.

• General treatment: Corrective treatment involves addressing underlying causes such as vitamin D deficiency and chronic renal failure.
• Pharmacological treatment: Drugs that lower calcium and parahormone levels include bisphosphonates, calcitonin, and corticosteroids.
• Surgical treatment: indicated in cases where there is significant hypercalcemia or severe symptoms, aimed at removing one or more parathyroid glands.
• Other types of treatment: may include dietary intervention and patient education on calcium control.

List of medications used to treat this disease

There are several medications used in the treatment of parathyroid hyperplasia:

• Bisphosphonates (eg, alendronate);
• Calcitonin;
• Cimetidine;
• Corticosteroids;
• Vitamin D and its derivatives (eg, calcitriol).

Disease monitoring

Monitoring of patients with parathyroid hyperplasia includes regular calcium and parathyroid hormone testing and evaluation of patients for complications. The prognosis with timely diagnosis and treatment is usually good, but relapses and serious complications such as osteoporosis and hypercalcemia are possible in persistent forms of the disease.

Age-related features of the disease

In children, hyperplasia of the parathyroid glands may be secondary and caused by various metabolic disorders. In older people, the disease is often associated with age-related changes in metabolism and is much more pronounced. In middle-aged groups, as a rule, clinical manifestations become less noticeable, but the risk of complications increases.

Questions and Answers

• What is parathyroid hyperplasia? Parathyroid hyperplasia is an increase in the volume of parathyroid tissue, which leads to elevated levels of parathyroid hormone and, consequently, hypercalcemia.
• What are the main symptoms of parathyroid hyperplasia? The main symptoms include fatigue, weakness, bone pain, changes in mental status and kidney problems.
• What factors can contribute to the development of this disease? Risk factors include age, gender, heredity, chronic kidney failure and vitamin D deficiency.
• How is parathyroid hyperplasia diagnosed? Diagnosis includes tests for calcium and parathyroid hormone levels, as well as radiological examinations such as ultrasound and CT.
• What is the treatment for parathyroid hyperplasia? Treatment can be medical (using a calcium-lowering drug) or surgical (removal of the parathyroid glands) if necessary.